.4Р38.1Р39.2Р胃食管交界Р27.3Р33.8Р30.6Р胃Р32.4Р28.1Р30.2Р局部晚期/转移性(%)Р9.1/90.9Р12.6/87.4Р10.8/89.2Р组织学:腺癌/未分化(%)Р98.9/1.1Р98.2/1.8Р98.6/1.4РREAL3一线治疗Р2017/11/25Р7Р疗效:mEOC-P和EOC两组的mPFS、ORR无显著差异РWaddell,et al, 2012, ASCO, oral abstract session, LBA4000Р100Р80Р60Р40Р20Р0Р0Р6Р12Р18Р24Р30Р36РEOC (n=275):中位PFS7.4个月?mEOC-P (n=278):中位PFS6.0个月РHR=1.22?95%CI=0.98-1.52?P=0.068Р时间(月)РPFS (%)РREAL3一线治疗Р2017/11/25Р9РEOC组?(n=269)РmEOC-p组(n=272)Р不良事件Р3级Р4级Р3级Р4级РP值Р感染*Р9.7%Р2.2%Р8.8%Р1.1%Р-Р发热性中性粒细胞下降**Р8.9%Р3.3%Р5.9%Р1.5%Р0.029Р中性粒细胞性下降Р18.2%Р10.8%Р8.1%Р5.9%Р<0.001Р贫血Р4.8%Р1.5%Р3.3%Р0.4%Р-Р血小板下降Р2.6%Р1.5%Р1.1%Р0.0%Р0.029Р低血钾Р5.2%Р1.9%Р3.3%Р1.1%Р-Р低血镁Р0.4%Р0.0%Р4.0%Р0.7%Р0.001Р安全性:血液学毒性РWaddell,et al, 2012, ASCO, oral abstract session, LBA4000Р*: 两组各有2例患者发生5级感染;?**: EOC组发生2例5级发热性中性粒细胞下降事件РREAL3一线治疗Р2017/11/25Р10
全文预览
